BBBT (Black Bird Biotech) LT-Debt-to-Total-Asset: 0.03 (As of Sep. 2023)


What is Black Bird Biotech LT-Debt-to-Total-Asset?

Black Bird Biotech BBBT -99.00% LT-Debt-to-Total-Asset is 0.03 as of Sep. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Black Bird Biotech's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.03.

Black Bird Biotech's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Sep. 2023 (0.03). It may suggest that Black Bird Biotech is progressively becoming more dependent on debt to grow their business.

Black Bird Biotech  (OTCPK:BBBT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Black Bird Biotech LT-Debt-to-Total-Asset Related Terms

Black Bird Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Black Bird Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Bird Biotech LT-Debt-to-Total-Asset Chart

Black Bird Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Black Bird Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.05 0.04 0.03

Black Bird Biotech LT-Debt-to-Total-Asset Calculation

Black Bird Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=0/0.219
=0.00

Black Bird Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=0.003/0.099
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.03 mean?
Black Bird Biotech (BBBT) has a LT-Debt-to-Total-Asset of 0.03 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Black Bird Biotech and its competitors.
Is Black Bird Biotech's LT-Debt-to-Total-Asset too high?
Black Bird Biotech's current LT-Debt-to-Total-Asset is 0.03.
How does Black Bird Biotech's LT-Debt-to-Total-Asset compare to BLMS and INLB?
Black Bird Biotech's LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Black Bird Biotech and its competitors. Black Bird Biotech's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Bird Biotech stock overvalued right now?
Black Bird Biotech (BBBT) has a current LT-Debt-to-Total-Asset of 0.03. The current LT-Debt-to-Total-Asset is 0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Black Bird Biotech (BBBT), the current LT-Debt-to-Total-Asset is 0.03 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Bird Biotech Business Description

Address 2801 E Camelback Road, Suite 200, Phoenix, AZ, USA, 85016
Black Bird Biotech Inc is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. In addition, it is the distributor in the U. S. and Canada for MiteXstream, an EPA-registered plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Its products include MiteXstream Biopesticide, Grizzly Creek Naturals, and Black Bird American Hemp.